Arie Belldegrun Overview

  • Investor Type
  • Angel

  • Status
  • Active

  • Professionals
  • 1

Professionals

  • Investments
  • 5

  • Exits
  • 4

Exits

Arie Belldegrun General Information

Description

Dr. Arie Belldegrun is a Co-Founder and serves as Senior Managing Director at Vida Ventures (Boston). He is the Founder and serves as Executive Chairman at Allogene Therapeutics. He co-founded and served as Chairman at Agensys. He is also a Co-Founder of Bellco Capital where he serves as Chairman. He also serves as Director at Symbiotic Capital. He is also Executive Chairman and Co-Founder of Allogene Therapeutics, a clinical-stage biotechnology company focused on pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. A visionary entrepreneur, he founded Kite Pharma, a biopharmaceutical company engaged in the development of innovative cancer immunotherapies, where he served as Chairman, President, and Chief Executive Officer until the acquisition of Kite by Gilead Sciences in October 2017. He has had a distinguished tenure in the life sciences, having been closely involved with the founding and advancement of several successful biopharmaceutical companies including Cougar Biotechnology and Agensys. Abiraterone, developed by Cougar, is a mainstay of therapy for patients with metastatic prostate cancer. He currently serves as a Partner & Chairman at Two River Group, UroGen Pharma, Kronos Bio, and Bellco Capital, and as co-Chairman of Breakthrough Properties. He is a Professor of Urology, holds the Roy and Carol Doumani Chair in Urologic Oncology, and is Director of the UCLA Institute of Urologic Oncology at the David Geffen School of Medicine at UCLA. Prior to joining UCLA, he was at the National Cancer Institute/NIH as a research fellow in surgical oncology and immunotherapy under Dr. Steven A. Rosenberg. He completed his MD at the Hebrew University Hadassah Medical School in Jerusalem, his post-graduate studies in Immunology at the Weizmann Institute of Science, and his residency in urologic surgery at Harvard Medical School. He has authored several books on oncology and more than 500 scientific and medical papers related to urological cancers, immunotherapy, gene therapy, and cancer vaccines. He is certified by the American Board of Urology and is a Fellow of the American College of Surgeons and the American Association of Genitourinary Surgeons. He served as a Chairman at Arno Therapeutics.

Business Details

Investor Status
Actively Seeking New Investments
Primary Investor Type
Angel (individual)
Corporate Office
  • Los Angeles, CA
  • United States

Arie Belldegrun Investments (5)

Company Name Deal Date Deal Type Deal Size Industry Company Stage Lead Partner
Kronos Bio 18-Jul-2019 Early Stage VC Biotechnology Generating Revenue/Not Profitable
Kronos Bio 23-May-2018 Biotechnology Generating Revenue/Not Profitable
Entera Bio 18-Oct-2017 Drug Delivery Generating Revenue/Not Profitable
Kite Pharma 20-Jun-2014 IPO Biotechnology Generating Revenue
Cell Design Labs Early Stage VC Biotechnology Generating Revenue

Arie Belldegrun Exits (4)

Company Name Exit Date Exit Type Exit Size
Kronos Bio 09-Oct-2020 IPO
Entera Bio 28-Jun-2018
Cell Design Labs 01-Dec-2017 Merger/Acquisition
Kite Pharma 03-Oct-2017 Merger/Acquisition

Arie Belldegrun Investments by Industry, Year, and Region

Investments by Industry

Investments by Year

Investments by Region

PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.

Arie Belldegrun FAQs

  • Who is Arie Belldegrun?

    Arie Belldegrun is an angel Investor who has made 5 investments.

  • What kind of investor is Arie Belldegrun?

    Arie Belldegrun is an angel investor.

  • What does Arie Belldegrun do?

    As an angel investor, Arie Belldegrun invests personal money into promising companies, typically in exchange for equity.

  • How many board seats does Arie Belldegrun hold?

    Arie Belldegrun holds 3 board seats including Ginkgo Bioworks, Urogen Pharma, and Nile Therapeutics.

  • What has Arie Belldegrun invested in?

    Arie Belldegrun has made numerous investments in companies like Kronos Bio, Entera Bio, and Kite Pharma within the Biotechnology and Drug Delivery industries.

  • What has Arie Belldegrun invested in recently?

    Arie Belldegrun's latest investment was on 18-Jul-2019 in Kronos Bio, a company within the Biotechnology industry.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »